Description
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Location: CPMC (San Francisco)
Please contact Clinicalresearch@sutterhealth.org about Study Lilly JVDE.
View study details on ClinicalTrials.gov
Principal Investigator
Recruitment Status
Active, Recruiting
Start Date
June 01, 2018